Trial Profile
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 651
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 04 Feb 2024 This trial has been discontinued in Italy (Global end date: 22 Sep 2022).
- 06 Oct 2023 This trial has been completed in Spain (Date of the global end of the trial : 2022-09-22), according to European Clinical Trials Database record.
- 19 Dec 2022 This trial has been completed in Poland (Date of the global end of the trial : 22-Sep-2022), according to European Clinical Trials Database record.